Sanofi - American Depositary Shares (SNY) closed at $47.04 on November 6, 2026, up 0.3% from the previous close, on volume of 3,630,460 shares (30-day average 4,177,358).
Data as of November 6, 2026.
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
Sanofi Advances Late-Stage Study of Belumosudil for Chronic Graft-versus-Host Disease
TipRanks (Fri, 6-Nov 11:31 AM ET)
Novavax gains after Q3 beat, guidance hike
Seeking Alpha News (Thu, 5-Nov 8:37 AM ET)
Bernstein Sticks to Their Buy Rating for Sanofi (SNYNF)
TipRanks (Wed, 4-Nov 9:09 AM ET)
Nurix falls as Sanofi scraps inflammatory disease drug
Seeking Alpha News (Wed, 4-Nov 7:26 AM ET)
Pfizer (PFE) Reports Q3 Earnings Tomorrow — Here’s Why Wall Street Remains Split
TipRanks (Mon, 2-Nov 7:02 AM ET)
RBC Capital Sticks to Their Hold Rating for Sanofi (SNYNF)
TipRanks (Mon, 2-Nov 1:26 AM ET)
PRNewswire (Thu, 29-Oct 7:30 AM ET)
Sanofi (SNY) Teams With ScionxBio to Pursue Long-Acting mRNA Candidates Using the TERA Platform
Market Chameleon (Tue, 20-Oct 5:29 AM ET)
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
Business Wire (Tue, 20-Oct 9:10 AM ET)
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sanofi - American Depositary Shares trades on the NASDAQ stock market under the symbol SNY.
As of November 6, 2026, SNY stock price climbed to $47.04 with 3,630,460 million shares trading.
SNY has a beta of 0.09, meaning it tends to be less sensitive to market movements. SNY has a correlation of 0.00 to the broad based SPY ETF.
SNY has a market cap of $112.60 billion. This is considered a Large Cap stock.
Last quarter Sanofi - American Depositary Shares reported $17 billion in Revenue and $2.04 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.41.
In the last 3 years, SNY traded as high as $60.12 and as low as $39.07.
The top ETF exchange traded funds that SNY belongs to (by Net Assets): AVDE, FENI, PPH, FVD, PID.
SNY has underperformed the market in the last year with a return of +0.9%, while SPY returned +9.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SNY shares. However, SNY has outperformed the market in the last 3 month and 2 week periods, returning +10.0% and +12.1%, while SPY returned -4.2% and -3.8%, respectively. This indicates SNY has been having a stronger performance recently.
SNY support price is $46.13 and resistance is $47.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNY shares will trade within this expected range on the day.
